Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the FDA-approved drug UNLOXCYT. The deal, expected to close in 2025, reflects Sun Pharma's strategy to strengthen its oncology presence and improve patient access to innovative treatments.